Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apyx Medical Corporation - Common Stock (NQ:APYX)

2.370 -0.210 (-8.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Apyx Medical Corporation - Common Stock

< Previous 1 2 3 4 Next >
Bronstein, Gewirtz & Grossman, LLC Notifies Apyx Medical Corporation (APYX) Investors of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Apyx Medical Corporation with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apyx Medical Corporation with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
APYX CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Apyx Medical Corporation
From The Law Offices of Frank R. Cruz
Via Business Wire
APYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Apyx Medical Corporation and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Apyx Medical Corporation (APYX) Investors
From Law Offices of Howard G. Smith
Via Business Wire
APYX CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Apyx Medical Corporation
From Glancy Prongay & Murray LLP
Via Business Wire
Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® Cosmetic Technology in Dermal Resurfacing Procedures
From Apyx Medical Corporation
Via Business Wire
Apyx Medical Corporation to Participate in Upcoming Investor Conferences in June
From Apyx Medical Corporation
Via Business Wire
NASDAQ:APYX Investor Notice: Investigation over Possible Securities Laws Violations by Apyx Medical Corporation
San Diego, CA -- (SBWIRE) -- 05/13/2022 -- Apyx Medical Corporation is under investigation concerning potential securities laws violations in connection with certain financial statements. 
Via SBWire
Apyx Medical Corporation Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook
From Apyx Medical Corporation
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Apyx Medical Corporation (APYX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Continues Investigation of Apyx Medical Corporation (APYX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Apyx Medical Corporation (APYX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
APYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Apyx Medical Corp. on Behalf of Apyx Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Apyx Medical Corporation (APYX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Apyx Medical Corporation (APYX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Apyx Medical Corporation (APYX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2022 Financial Results on May 12, 2022
From Apyx Medical Corporation
Via Business Wire
Apyx Medical Corporation Announces FDA 510(k) Submission with Clinical Study Support for the Use of the Renuvion® APR Handpiece for Aesthetic Procedures to Improve Appearance of Lax Skin
From Apyx Medical Corporation
Via Business Wire
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2021 Financial Results; Introduces Full Year 2022 Financial Outlook
From Apyx Medical Corporation
Via Business Wire
Apyx Medical Corporation Notified of Pending FDA Medical Device Safety Communication Related to its Advanced Energy Products
From Apyx Medical Corporation
Via Business Wire
Apyx Medical Corporation Announces Peer-Reviewed Publication Featuring Results from the U.S. IDE Clinical Study Evaluating the Renuvion® Dermal Handpiece Using Apyx’s Helium Plasma Technology for Dermal Resurfacing Procedures
From Apyx Medical Corporation
Via Business Wire
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 17, 2022
From Apyx Medical Corporation
Via Business Wire
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2021 Revenue Results
From Apyx Medical Corporation
Via Business Wire
Apyx Medical Corporation Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Outlook
From Apyx Medical Corporation
Via Business Wire
Apyx Medical Corporation to Participate in Upcoming Investor Conferences in November and December
From Apyx Medical Corporation
Via Business Wire
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2021 Financial Results on November 11, 2021
From Apyx Medical Corporation
Via Business Wire
Apyx Medical Corporation to Participate in the Colliers Securities 2021 Institutional Investor Conference
From Apyx Medical Corporation
Via Business Wire
Apyx Medical Corporation Announces Appointment of Wendy Levine to the Company’s Board of Directors
From Apyx Medical Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.